fashion -WSS

fashion

author：Wikipedia 2025-10-01 22:39:19 - browse：3

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Choosing scientific sides in the fight against Alzheimer's

focus

WSS

Germany receives 178 compensation applications from gay servicepeople over discrimination

Neutralizing antibodies against HIV shows promise in children

Neutralizing antibodies against HIV shows promise in children

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

What to know about a major upcoming Wegovy heart health study

hotspot

fashion

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

Alkermes shareholders re

Choosing scientific sides in the fight against Alzheimer's

BioMarin wins approval for gene therapy to treat hemophilia A

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Medicare details structure of new drug price negotiation program

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

After affirmative action ruling, medical educators look to 'holistic review'

Discs beat pads, tampons for heavy menstrual flow, new study shows

entertainment

Travel bans should be based on evidence, not politics or fear

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Rare Northern Lights show in US this week: Where and how to see it

FDA approves Leqembi, a milestone in Alzheimer’s treatment

The painfully weak evidence on taking collagen to treat arthritis

Neutralizing antibodies against HIV shows promise in children

focus

focus

focus

explore